Skip to main content
Premium Trial:

Request an Annual Quote

ATCC Inks NCI Biomaterials Processing Contract

NEW YORK — Nonprofit biological resource and standards organization ATCC said on Tuesday that it has signed a contract to provide biomaterial processing support to the National Cancer Institute's Division of Cancer Epidemiology and Genetics (DCEG) Field and Biospecimen Support Services.

Under the contract, ATCC will compete to provide technical support for studies and other research activities associated with ongoing and new research programs conducted in DCEG branches and laboratories. Such programs involve epidemiology, exposure assessment, genetics, and clinical research, the Manassas, Virginia-based organization said.

Specifically, ATCC will coordinate specimen receipts and perform molecular assays to characterize the specimens, as well as provide support services for the procurement, storage, and shipment of specimens to and from international and domestic specimen sites. It will also prepare specimens for transport to testing laboratories by aliquoting, labeling, and batching.

Additional terms of the arrangement were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.